Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

NCT06905834 is registered in ClinicalTrials.gov with Instituto de Investigación Biomédica de Salamanca as lead sponsor.

NCT NCT06905834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06905834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
Lead sponsor
Instituto de Investigación Biomédica de Salamanca
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
June 30, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease (ded), graft-versus-host disease(gvhd)